Related Experiment Videos
[Total-body hyperthermia and combined anticancer chemotherapy]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 1, 1985
Summary
Extracorporeally induced total-body hyperthermia (TBHT) shows significant efficacy in treating advanced lung and liver cancers. Combining TBHT with chemotherapy, guided by human tumor stem cell assays, enhances anticancer effects and improves drug delivery.
Area of Science:
- Oncology
- Thermotherapy
- Cancer Treatment
Context:
- Far-advanced cancers present significant treatment challenges.
- Extracorporeally induced total-body hyperthermia (TBHT) is an emerging therapeutic modality.
- Japanese clinical data provides insights into TBHT efficacy.
Purpose:
- To evaluate the efficacy of extracorporeally induced total-body hyperthermia (TBHT) in treating far-advanced cancers.
- To analyze the effectiveness of TBHT based on cancer site and in combination with chemotherapy.
- To explore methods for optimizing TBHT and chemotherapy combinations.
Summary:
- TBHT demonstrated notable anticancer effects, particularly in lung and liver cancers, regardless of primary or secondary tumorigenesis.
- Combining TBHT with cis-diamminedichloroplatinum (cis-DDP) significantly enhanced anticancer outcomes.
- The human tumor stem cell assay proved valuable for selecting thermosensitive and thermochemosensitive agents.
- Angiotensin II-induced hypertensive chemotherapy during TBHT was highlighted for improving selective drug delivery to tumors.
Impact:
- TBHT shows promise as an effective treatment for specific advanced cancers.
- Optimized combination therapies, guided by personalized assays, can improve patient outcomes.
- Novel drug delivery strategies, like hypertensive chemotherapy during TBHT, warrant further investigation.